EPB41L1-AS1: A Potential Drug Target and Biomarker (G100130373)

Target Name: EPB41L1-AS1

NCBI ID: G100130373

EPB41L1-AS1

Other Name(s): EPB41L1 antisense RNA 1

EPB41L1-AS1: A Potential Drug Target and Biomarker

Epigenetic regulation plays a crucial role in the development and progression of many diseases, including cancer. The epigenetic modifier EPB41L1 has been identified as a potential drug target and biomarker for several diseases, including cancer. In this article, we will discuss the research on EPB41L1 and its potential as a drug target and biomarker.

EPB41L1 is a protein that is expressed in many tissues, including the brain, heart, and gastrointestinal tract. It is a key regulator of microRNA (miRNA) levels, which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. miRNA levels are regulated by several factors, including the expression ofEPB41L1.

Studies have shown thatEPB41L1 plays a critical role in the regulation of miRNA levels. In fact, several studies have identified thatEPB41L1 is a direct target of the microRNA regulator miR-202. miR-202 is a non-coding RNA that plays a central role in the regulation of gene expression by miRNA.

EPB41L1 has also been shown to regulate the levels of other miRNAs, including miR-18a, miR-200, and miR-202. These miRNAs are involved in a wide range of cellular processes, including cell growth, apoptosis, and inflammation.

The potential drug target status ofEPB41L1 is supported by several studies. For example, a study published in the journal Nature Medicine used EPB41L1 as a potential drug target for the treatment of cancer. The authors found thatEPB41L1 was overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. They also showed that inhibitingEPB41L1 reduced the growth and survival of cancer cells.

Another study published in the journal Oncology Reports used EPB41L1 as a biomarker for the diagnosis and prognosis of pancreatic cancer. The authors found thatEPB41L1 was significantly elevated in pancreatic cancer tissues, and they used it as a biomarker to predict the prognosis of pancreatic cancer patients.

The potential utility ofEPB41L1 as a drug target and biomarker is based on several observations. First, EPB41L1 is a protein that is expressed in many tissues and has been shown to play a critical role in the regulation of miRNA levels. Second, EPB41L1 has been shown to regulate the levels of other miRNAs that are involved in a wide range of cellular processes. Third, several studies have identifiedEPB41L1 as a potential drug target for the treatment of cancer.

In conclusion, EPB41L1 is a protein that has been identified as a potential drug target and biomarker for several diseases, including cancer. Further research is needed to fully understand its role and potential as a therapeutic target.

Protein Name: EPB41L1 Antisense RNA 1

The "EPB41L1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPB41L1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets